Intravesical recurrence in upper tract urothelial carcinoma patients after radical nephroureterectomy in Rajavithi Hospital
DOI:
https://doi.org/10.52786/isu.a.67Keywords:
Upper tract urothelial carcinoma, intravesical recurrence, nephroureterectomy, predictive factorsAbstract
Objective: Upper tract urothelial carcinoma (UTUC) is a malignant disease which is challenging to manage. The modalities for diagnosis and accurate clinical staging are limited, radical nephroureterectomy (RNU) with bladder cuff excision being the gold standard for treatment of UTUC. Subsequent intravesical recurrence (IVR) following RNU is a common problem. This study investigated the risk factors that affect IVR in Rajavithi Hospital. The objective of this study is to investigate whether the risk factors affect intravesical recurrence in UTUC patients after RNU.
Materials and Methods: This retrospective study evaluated 94 patients who had undergone RNU in Rajavithi Hospital for UTUC between November 2006 and February 2021; 69 patients were included in the analysis. Data was analyzed to investigate risk factors that impact IVR and IVR-free survival using Kaplan-Meier and Cox proportional regression methods.
Results: Out of 69 patients, at a mean follow up of 24 months, IVR occurred in 27 patients (39.1%). The overall postoperative 5-year IVR-free survival was 51.3%. Multivariate analysis indicated significant risk factors were high- grade tumor (adjusted HR = 3.47, 95%CI: 1.12-10.76, p = 0.031), ureterorenoscopy (URS) (adjusted HR = 3.45, 95%CI: 1.35-8.81, p = 0.01) and tumor multifocality (adjusted HR = 2.75, 95%CI: 1.02-7.38, p = 0.045). Postoperative 5-year IVR-free survival was significantly different for high-grade tumor compared with low-grade tumor (36.6% vs 82%, p = 0.006) and multiple tumors compared with a solitary tumor (18.4% vs 68.8%, p = 0.003) but there was no significant difference in URS compared with no URS (46.3% VS 51.6, p = 0.158).
Conclusion: The risk factors that affect intravesical recurrence in UTUC patients after Radical nephroureterectomy are high-grade tumor, tumor multifocality, and URS.
References
Tan P, Xie N, Yang L, Liu L, Tang Z, Wei Q. Diagnostic ureteroscopy prior to radical nephroureterectomy for upper tract urothelial carcinoma increased the risk of intravesical recurrence. Urol Int 2017;100:92-9.
Margulis V, Shariat S, Matin S, Kamat A, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration. Cancer 2009;115:1224-33.
Zigeuner R, Hutterer G, Chromecki T, Rehak P, Langner C. Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location. BJU Int 2006; 98:1181-6.
Xylinas E, Rink M, Cha E, Clozel T, Lee R, Fajkovic H, et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2014;65:210-7.
Novara G, De Marco V, Dalpiaz O, Gottardo F, Bouygues V, Galfano A, et al. Independent predictors of metachronous bladder transitional cell carci- noma (TCC) after nephroureterectomy for TCC of the upper urinary tract. BJU Int 2008;101:1368-74.
Xylinas E, Colin P, Audenet F, Phe V, Cormier L, Cussenot O, et al. Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol 2013;31:61-8.
Seisen T, Granger B, Colin P, Léon P, Utard G, Renard-Penna R, et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015; 67:1122-33.
Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 2015;68:868-79.
Rouprêt M, Babjuk M, Burger M, Capoun O, Cohen D, Compérat E, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 2021;79:62-79.
Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol 2014;65:650-8.
Ishioka J, Saito K, Kijima T, Nakanishi Y, Yshida S, Yokoyama M, et al. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int 2015;115:705-12.
Fradet V, Mauermann J, Kassouf W, Rendon R, Jacobsen N, Fairey A, et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the canadian upper tract collaboration. Urol Oncol 2014;32:839-45.
Lee CH, Ku JY, Jeong CW, Ku JH, Kwak C, Kim HH, et al. Predictors for intravesical recurrence following radical nephroureterectomy for upper tract urothelial carcinoma: a national multicenter analysis. Clin Genitourin Cancer 2017;15:e1055-61.
Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyma T, Yocshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993;342:1087-8.
Jones T, Wang M, Eble J, MacLennan G, Lopez-Beltran A, Zhang S, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11:6512-9.
Fang D, Xiong GY, Li XS, Chen XP, Zhang L, Yao L, et al. Pattern and risk factors of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a large Chinese center experience. J Formos Med Assoc 2014;113:820-7.
Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005;65:279-83.
Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, et al. Effect of tumor location on prognosis in patients treated with radical nephro- ureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 2010;58:574-80.
Lughezzani G, Sun M, Perrotte P, Shariat SF, Jeldres C, Budus L, et al. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. Urology 2010;75:321-7.
Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2014;65:210-7.
Shariat SF, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Raman JD, et al. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. BJU Int 2010;105:1672-7.
Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 2010;57:1064-71.
Yuan H, Chen X, Liu L, Yang L, Pu C, Li J, et al. Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carci- noma: a meta analysis. Urol Oncol 2014;32:989-1002.
Chen XP, Xiong GY, Li XS, Matin SF, Garcia M, Fang D, et al. Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China. BJU Int 2013;112:917-24.
Liu P, Su XH, Xiong GY, Li XS, Zhou LQ. Diagnostic ureteroscopy for upper tract urothelial carcinoma is independently associated with intravesical recur- rence after radical nephroureterectomy. Int Braz J Urol 2016;42:1129-35.
Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol 2010;183:56-61.
O’Brien T, Ray E, Singh R, Coker B, Beard R, British association of urological surgeons section of oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective,multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011;60:703-10.
Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP monotherapy study group trial. J Clin Oncol 2013;31:1422-7.
Zabell J, Konety BR. Management strategies for non-muscle-invasive bladder cancer (Ta, T1, and CIS). In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, editors. Campbell-Walsh-Wein Urology. 12th ed. Pennsylvania: Elsevier; 2020. p. 3091-111.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Insight Urology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
